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Background: Candidiasis is the most frequent mycotic infection of the oral cavity. The aim of this study 
was to investigate the presence of clinical oral candidiasis and Candida albicans yeast in a population diag-
nosed of primary Sjögren’s syndrome (pSS) and to study the possible factors associated with this infection.
Material and Methods: An observational cross-sectional study was conducted in 61 pSS patients (60 women, 
1 man, mean age 57.64±13.52) where patient based information (demographic and medical, tobacco and al-
cohol consumption history), intraoral parameters (presence of dentures, clinical signs of candidiasis), sali-
vary analytical information (number of Candida albicans as colony-forming units per millilitre (CFU/mL), 
salivary pH levels, unstimulated whole saliva (UWS) and stimulated whole saliva (SWS) were collected.
Results: 13.1% of pSS patients presented oral signs of candidiasis. Denture stomatitis and angular cheilitis were the most 
common lesions. 87.5% of patients with clinical candidiasis presented reduced pH levels and salivary flow in both UWS 
and SWS. A significant statistical negative correlation was found between CFU/mL of Candida albicans and levels of 
UWS and SWS. A negative correlation was found between pH levels and CFU/mL, although not statistically significant.
Conclusions: A reduced salivary flow may predispose pSS patients to Candida albicans overgrowth, which may 
show with clinical signs. Preventive measures are of great importance to avoid and to treat this condition promptly.
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Introduction
Primary Sjögren’s syndrome (pSS) is a systemic 
autoimmune exocrinopathy that damages the salivary 
and lacrimal glands, resulting in dry eyes and 
hyposalivation (1,2). Saliva contains IgA, lysozyme and 
lactoferrin, which are important antimicrobial defence 
mechanisms. Moreover, proper levels of saliva allow 
the lubrication of the mucosa and its buffering capacity 
maintains a physiological pH within the oral cavity 
(3,4). In pSS patient’s salivary gland hypofunction 
reduces the concentrations of immunoglobulins 
and other electrolytes (5), thus making the mucous 
membranes more exposed to the oral microbiota, and 
specifically to Candida infections (6). Candida species 
are commensal yeast present in the oral flora of healthy 
population. Nevertheless, in SS patients its prevalence 
has been estimated to be higher (7,8). Therefore, 
simple identification of Candida yeast does not prove 
any infection and it is not always associated with the 
presence of clinical oral candidiasis (9). Candidiasis 
is the most frequent mycotic infection of the oral 
cavity, and it is usually diagnosed clinically, based on 
recognition of related lesions (9). The pathogenesis of 
this infection is still not fully understood, but a variety 
of systemic (as immunosuppression or endocrine 
disorders) and local factors (reduced salivary flow, use 
of dentures, high sugar diet, among others) have been 
associated to an overgrowth of Candida species, being 
Candida albicans the species most often associated with 
oral lesions (10,11). This variety of predisposing factors 
alters to an environment that favours proliferation of 
Candida and leads to its transition from commensal 
to pathogenic, which may show with clinical signs 
and symptoms of oral candidiasis (9). The reported 
prevalence of clinical oral candidiasis in SS has varied 
widely (0%-80%), mainly due to three factors: the lack 
of a clear symptomatology, patient related factors (such 
as oral hygiene habits) and different criteria used for 
diagnosing oral candidiasis in the literature (12).
Therefore, the main objective of this observational 
study was to investigate in a cohort of patients with pSS 
the association between the presence of C. albicans and 
clinical lesions of oral candidiasis with their salivary 
flow rates and pH levels. We also studied the possible 
influence of patient-related factors in the development 
of clinical oral candidiasis.
Material and Methods 
- Study design, setting and subjects
A cross-sectional observational study was conducted 
following STROBE guidelines, as part of the EPOX-
SSp project (13). The patient cohort was the same as in 
a previous study carried out by this research group (14). 
This sample consisted on consecutive patients who at-
tended at different rheumatology services in the Com-
munity of Madrid (Spain) and which met the following 
inclusion criteria: being over 18 years old and being 
diagnosed of pSS according to the diagnostic criteria 
proposed by the American European Consensus Group 
(AECG) in 2002 (15). If selected patients had any other 
connective tissue disease or difficulties to attend to the 
School of Dentistry were excluded.
- Clinical variables and clinical diagnosis of oral can-
didiasis
A standard clinical protocol was applied and the 
following variables were recorded:
a) Patient related: age and gender, medical history, type 
and number of medicines, alcohol and tobacco con-
sumption and wear and type of denture.
b) pSS disease: pSS AECG-2002 diagnostic criteria, 
time from diagnosis, serological data (rheumatoid fac-
tor, immunoglobulins alteration, antinuclear autoanti-
bodies), and systemic manifestations of pSS (parotid 
enlargement, musculoskeletal, skin, lung, renal, central 
nervous system, peripheral nervous system, haemato-
logical, gastrointestinal or cardiac involvement).
c) Oral symptoms: xerostomia, dysphagia, dysgeusia 
and glossodynia.
A complete facial and intraoral mucosa examination was 
carried out by one calibrated specialist in oral medicine 
(JS). Diagnosis of clinical oral candidiasis was based 
on presence of the following clinical presentations: 
pseudomembranous candidiasis, acute erythematous 
candidiasis, chronic erythematous candidiasis (denture 
stomatitis), chronic hyperplastic candidiasis and 
secondary forms of oral candidiasis (angular cheilitis, 
median rhomboid glossitis and chronic mucocutaneous 
candidiasis) (11).
- Saliva Sampling
Stimulated (SWS) and unstimulated saliva (UWS) were 
collected by one specialist in oral medicine (LR). Pa-
tients were told not to eat, drink, smoke or brush their 
teeth 90 minutes prior the appointment. Samples were 
obtained in the morning, between 8.00 and 10.00 am, 
with the UWS sample always collected first during 15 
minutes. To collect the SWS sample patients were asked 
to chew a paraffin gum and continuously spit out the 
saliva into a plastic container for 10 minutes. Flow rates 
were recorded as mL/min. Hyposalivation was defined 
as a flow rate <0.7 mL/min for SWS and <0.1 mL/min 
for UWS (14). To measure the salivary pH a pH meter 
was used (MicroPh2001, CRISON).
- Microbial sampling, culturing, and quantification of 
yeasts
Microbial samples were taken by rubbing a sterile 
cotton swab along the dorsal surface of the tongue of 
all patients. All swabs were taken by one operator (JS) 
before the saliva collection. Samples were transferred 
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- Oral candidiasis and salivary flow rates
Table 2 shows the association between the presence of 
clinical oral candidiasis and UWS and SWS flow rates 
as well as with hyposalivation. pSS patients with oral 
candidiasis suffered more UWS and SWS hyposaliva-
tion and had lower flow rates compared with those with-
out clinical oral candidiasis. A statistically significant 
association between clinical oral candidiasis and SWS 
hyposalivation was found.
- CFU/mL, salivary flow rates and pH levels
A statistically significant negative correlation was 
found between the amounts of C. albicans in CFU/mL 
and the salivary flow levels of SWS (r=-0.317; p=0.013) 
and UWS (r=-0.339; p=0.008) (Fig. 1). A negative cor-
relation between C. albicans and salivary pH levels was 
also found (r=-0.225; p=0.08), but without reaching sta-
tistical significance (Fig. 1).
Fig. 1: (A) Correlation between SWS and Candida albicans CFU/
mL, (B) Correlation between UWS and Candida albicans CFU/mL, 
(C) Correlation between salivary pH levels and Candida.
into a vial containing 1mL RTF (reduced transport fluid), 
vortexed for 30 seconds in a mixer for homogenizing 
the collection and then aliquots of 0.02mL of suspension 
were plated onto Sabouroud Agar plates (Sabouraud 
Dextrose Agar- DIFCO) and incubated at 37°C for 24-
48 hours. After incubation, colony-forming units per 
millilitre (CFU/mL) of C. albicans were counted. All 
samples were analysed at the Microbiology Laboratory 
of Faculty of Odontology at the University Complutense 
of Madrid.
- Statistical analysis
The sample size calculation (shown in a previous study 
by the same research group) (14) was calculated con-
sidering the data on prevalence of oral candidiasis 
(29.9%) reported by Likar-Manookin et al. (3). Since 
this study did not compare oral candidiasis with a con-
trol group we used the percentage of oral candidiasis 
of the study of López-Pintor et al., which also com-
pared the presence of oral candidiasis in renal trans-
plant patients with a control group (4.19%) using the 
same methodology (16). If we consider an α =0.05 and 
a statistical power of 90%, 35 patients will be needed 
in each group. If we consider a 15% loss, 41 patients 
will be needed per group.
The categorical variables were described by their num-
ber and percentage and the quantitative variables by 
their media ± standard deviation (SD). The Kolmogorov-
Smirnoff test was applied to establish their goodness of 
fit to normality. To determine the differences between 
those pSS patients suffering from clinical oral candidia-
sis from those not suffering in regards to the categorical 
variables, the chi-squared test or Fisher’s exact test were 
used. When assessing the differences in the quantitative 
variables, the U Mann-Whitney test was used. Spear-
man’s rank correlation (r) coefficients were calculated 
to explore the associations between the quantitative 
variables. Differences were considered significant if p 
was ≤ 0.05. All data were analysed using SPSS 25.0 for 
Windows.
Results
- Participants and descriptive data
All demographic data, pSS characteristics, systemic 
and serological manifestations from the selected pa-
tients are depicted in Table 1.
- Oral candidiasis in pSS
Clinical signs of oral candidiasis were present in 13.1% 
of pSS patients. Denture stomatitis was the most preva-
lent lesion (8.2%), followed by angular cheilitis (4.9%) 
and median rhomboid glossitis (1.6%). No relationship 
was found between the clinical signs of oral candidiasis 
and the pSS variables. No other associations were ob-
served between the rest of variables and the presence of 
clinical oral candidiasis (Table 1).
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Patients with OC (n=8) Patients without OC (n=53) p
pSS characteristics (AECG-2002)
Oral symptoms 8 (100%) 51 (96.2%) 1c
Ocular symptoms 8 (100%) 53 (100%) 1c
Oral signs 5 (62.5%) 27 (50.9%) 0.71c
Ocular signs 7 (87.5%) 46 (86.8%) 0.95b
Histopathology 6 (75%) 26 (49.1%) 0.26c
Autoantibodies (anti-Ro/ anti-La) 7 (87.5%) 48 (90.6%) 0.78b
pSS systemic manifestations
Whatever systemic manifestations 5 (62.5%) 28 (52.8%) 0.7c
Parotid enlargement 4 (50%) 16 (30.2%) 0.26b
Musculoskeletal involvement 1 (12.5%) 28 (52.8%) 0.05c
Skin involvement 0 14 (26.4%) 0.09b
Lung involvement 1 (12.5%) 4 (7.5%) 0.51c
Renal involvement 0 3 (5.7%) 1c
Central nervous system involvement 0 1 (1.9%) 1c
Peripheral nervous system involvement 0 2 (3.8%) 1c
Haematological involvement 3 (37.5%) 15 (28.3%) 0.59b
Gastrointestinal involvement 0 3 (5.7%) 1c
Cardiac involvement 0 0 -
pSS serological manifestations
FR+ 3 (37.5%) 30 (56.6%) 0.45b
ANA+ 7 (87.5%) 49 (92.5%) 0.5b
Modified immunoglobulins 5 (62.5%) 31 (58.5%) 1c
Other variables
Smokers 0 8 (15.1%) 0.58c
Alcohol intake 3 (37.5%) 10 (18.9%) 0.35c
Antidepressant treatment 1 (12.5%) 6 (11.3%) 0.92b
Antihypertensive treatment 1 (12.5%) 11 (20.8%) 1c
Diabetes patients 0 3 (5.7%) 1c
Patients with dentures 3 (37.5%) 10 (18.9%) 0.23b
Acrylic denture 0 5 (9.4%) 0.15b
Metallic denture 2 (25%) 3 (5.7%) 0.15b
Implant-supported denture 1 (12.5%) 1 (1.9%) 0.15b
Acrylic and metallic denture 0 1 (1.9%) 0.15b
Values are number (%) of patients. OC: oral candidiasis; RF: Rheumatoid Factor; ANA: Antinuclear autoantibodies. Statistical test: bChi-squared 
test or cFisher’s exact test.
pSS patients with OC (n=8) pSS patients without OC (n=53) p
UWS hyposalivation
 Yes 7 (87.5%) 30 (56.6%)
0.09b
 No 1 (12.5%) 23 (43.4%)
UWS flow rate mL/min (mean±SD) 0.05±0.11 0.13±0.17 0.15a
SWS hyposalivation 
Yes 7 (87.5%) 27 (50.9%) 0.05b
 No 1 (12.5%) 26 (49.1%)
SWS flow rate mL/min (mean±SD) 0.36±0.69 0.73±0.67 0.08a
Values are number (%) and mean ± standard deviation (SD). Statistical test: a U-Mann-Whitney test, b Fisher’s exact test. OC: oral candidiasis, 
UWS: Unstimulated whole saliva, SWS: stimulated whole saliva.
Table 1: Differences between patients with and without oral candidiasis (OC).
Table 2: Relationship between oral candidiasis and salivary variables.
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- Oral candidiasis and oral symptoms
100% of pSS patients with clinical oral candidiasis also 
suffered xerostomia (p=0.3), 50% dysphagia (p=0.7) 
and glossodynia (p=0.27), but none referred dysgeusia 
(p=0.28). The association between having clinical oral 
candidiasis and symptoms of oral discomfort was not 
statistically significant, although xerostomia was al-
ways present.
Discussion
This cross-sectional study on a cohort of pSS patients has 
found a significant inverse relationship between UWS and 
SWS levels and C. albicans counts. Hyposalivation is one 
of the main manifestations of SS. When salivary secretion 
is diminished, not only the volume of saliva decreases, 
but also its composition is altered, which may result in 
changes of the normal microflora homeostasis (17,18). 
Hence, the predisposition of patients with decreased 
salivary flow to oral candidiasis could be attributed 
not only to the lack of mechanical washing activity but 
also to the lack of protective salivary factors (19-21).
Hyposalivation has been associated with an increase 
in oral Candida counts (6), but, specifically in SS, 
it is not clear whether these high Candida levels are 
associated to lower UWS and/or decreased SWS flow 
rates. In fact, some authors have studied both types of 
saliva in pSS patients and have reported high Candida 
counts associated to both lower rates of SWS and UWS, 
although without demonstrating statistical significance 
(22,23). Similarly, there are studies reporting that when 
C. albicans is higher UWS is decreased (2,24,25), some 
demonstrating a significant relationship (2,25). In other 
studies, however, the association was with SWS rather 
than UWS (26). In the present study, we have analysed 
both UWS and SWS and we have found a significant 
inverse relationship with C. albicans. These previous and 
present results emphasize the importance to frequently 
monitor the salivary flow rates in pSS patients to prevent 
superinfections by C. albicans. The clinical results from 
this study have further confirmed that hyposalivation 
is associated with clinical oral candidiasis. 87.5% of 
patients with clinical oral candidiasis presented SWS 
hyposalivation, compared to 50.9% pSS patients with 
a healthy mucosa. Similarly, 87.5% of patients with 
oral clinical candidiasis had UWS hyposalivation, 
compared to 56.6% without. As in previous reports (25) 
we have observed that pSS patients with low salivary 
flow rates had a higher risk for developing clinical oral 
candidiasis, with a statistical association between the 
SWS flow rate and oral candidiasis, however not with 
the UWS. In regard to other variables studied, we did 
not find any association between pSS related outcomes 
and clinical oral candidiasis. This is in agreement with 
Billings et al. who found that hyposalivation both UWS 
and SWS was significantly associated with clinical 
oral candidiasis, but not with other variables such as 
presence of autoantibodies and focus score (7).
It is accepted that Candida adherence to epithelial and 
acrylic surfaces is enhanced in the presence of low pH 
levels and salivary flow rate (27), nevertheless, very few 
studies have reported values of pH levels in SS patients 
(5). To our knowledge, this is the first report that com-
pares pH levels in pSS patients with clinical signs of 
candidiasis or C. albicans loads. Low salivary pH val-
ues in SS may be caused by the low salivary flow rates 
and the decreased buffering capacity, although it is also 
possible that the progressive destruction of the salivary 
gland tissue may have a direct effect on the pH sali-
vary secretion. In this investigation pSS patients with 
clinical oral candidiasis had lower pH levels (4.40±2.91) 
than those without (5.19±2.80) although these differ-
ences were not statistically significant. Similarly, when 
studying the association between C. albicans counts 
and pH levels, the lower the salivary pH the higher were 
the C. albicans counts. The lack of a significant associa-
tion may be due to the variable ranges in pH described 
for a favourable Candida growth, between 3 to 8 (28). 
Another explanation may be due to the confounding 
effect of oral hygiene products, such as toothpastes or 
mouthwashes that compensate the drop in pH in these 
patients. More articles are needed to elucidate the pos-
sible relationship between pH levels and buffer capacity 
with Candida overgrowth and infection.
Although high Candida counts are predictive for clini-
cal oral candidiasis (6), there is no relevant information 
on the critical yeast counts necessary to evidence the 
clinical signs of oral candidiasis (29). A recent study 
published by Zhou et al. (29) concluded that 266 CFU/
mL of C. albicans in saliva samples could be used as a 
threshold. In our study all patients with clinical signs of 
candidiasis had more than 266 CFU/mL. New studies 
where the relationship of C. albicans counts and clinical 
signs of oral candidiasis should be carried out, in or-
der to unify a cut-off point for considering C. albicans 
counts as an infection.
The present study has some limitations. The first is the 
cross-sectional nature of this investigation. Another 
limitation is the lack of a control non-pSS group. Be-
sides, it should be noted that the low rate of clinical oral 
candidiasis observed in the current study may be due to 
good oral hygiene of the patients studied, 90% of includ-
ed pSS patients brushed their teeth at least twice a day.
In conclusion, this study shows how a lower salivary 
flow is related to higher counts of C. albicans. Since this 
oral condition may be symptomless, it is highly recom-
mended the frequent monitoring and the emphasis of 
increased oral hygiene practices in these patients. In-
tervention prospective studies are needed to assess the 
impact of these enhanced oral preventive measures on 
the incidence of oral clinical candidiasis.
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